American patients reported new types of mutations after being treated with the “CAR-T” method.
The FDA (Food and Drug Administration), the most important American health body, has reported that a cancer treatment can, in itself, be the cause of fatal mutations in the disease.
According to the organization, 19 reports of new types of cancer have been received in patients undergoing a treatment called CAR-T, a method approved in 2017 and used primarily to fight blood cancers.
In Brazil, the medical community refers to the treatment as “CAR-T cell therapy.” It is nothing more than a modality of immunotherapy, which uses defense cells genetically modified and reprogrammed in the laboratory to destroy tumors. The application is carried out in a single dose, by intravenous infusion.
In the national territory, the indications for the use of this treatment are patients with diffuse large B-cell lymphoma and acute lymphoblastic leukemia.
Experts have reported that this treatment has already saved the lives of millions of people, and although there is a causal link between the method and a small risk of disease, the benefits outweigh the risks.
Another explanation put forward by the American body is that, since the therapy is used in patients who have already undergone at least one cycle of conventional chemotherapy treatments, these treatments would be the cause of new types of cancer.
The FDA did not provide details of the investigation but said it was “evaluating the need for regulatory action.”
9 collagen-rich foods to consume for healthier skin
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
